The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) nonprofit organization that develops and sponsors Master Protocols and Adaptive Platform Trials. GCAR aims to modernize clinical trials for more efficient, less costly drug development, ultimately speeding up the process from lab discovery to patient treatment.
2017
82-1199380
$59.58 million
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
A global adaptive clinical trial aimed at accelerating the discovery of new treatments for glioblastoma patients.
A platform trial aimed at evaluating multiple treatments for COVID-19 patients worldwide.
An innovative clinical research effort to accelerate treatment development for ovarian cancer patients.
Clinical Trial Collaborations
Successful partnerships with diverse stakeholders, including biotech/pharma, health authorities, and clinical researchers.
Patient Participation
Engagement of patients in ongoing and innovative clinical trials.
Adaptive Trials Implementation
Introduction of new adaptive trial designs to improve the efficiency of drug development.
Overall Score
63
48
/100
Program Expense Ratio
91.26%
20
/20
Program Revenue Growth
-30.22%
2
/20
Leverage Ratio
0.3291
12
/20
Working Capital Ratio
1.346
12
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2023
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 3.081M | 10.71% |
Program Services | 23.96M | 83.27% |
Investment Income | 1.733M | 6.02% |
Sales of Non-Inventory Assets | 0 | 0.00% |
Other Notable Sources | 0 | 0.00% |
Total Revenue | 28.78M | 100.00% |
Med Research
Brain ResearchMed Research
Brain ResearchMed Research
Brain ResearchMed Research
Brain ResearchMed Research
Brain Research